4.9800
+0.0100
+(0.20%)
At close: April 17 at 4:00:00 PM EDT
4.9700
-0.01
(-0.20%)
After hours: April 17 at 5:39:02 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
37,862
37,862
100,387
91,496
54,522
Cost of Revenue
22,563
22,563
16,918
26,219
21,908
Gross Profit
15,299
15,299
83,469
65,277
32,614
Operating Expense
120,841
120,841
300,172
328,185
346,123
Operating Income
-105,542
-105,542
-216,703
-262,908
-313,509
Net Non Operating Interest Income Expense
10,875
10,875
12,413
2,932
88
Other Income Expense
37,420
37,420
-13,280
5,823
21,208
Pretax Income
-57,247
-57,247
-217,570
-254,153
-292,213
Net Income Common Stockholders
-57,247
-57,247
-217,570
-254,153
-292,213
Diluted NI Available to Com Stockholders
-57,247
-57,247
-217,570
-254,153
-292,213
Basic EPS
-1.83
-1.10
-4.42
-7.13
-12.44
Diluted EPS
-1.83
-1.10
-4.42
-7.13
-12.44
Basic Average Shares
51,983.5000
52,218
49,276
35,637
23,499
Diluted Average Shares
51,983.5000
52,218
49,276
35,637
23,499
Total Operating Income as Reported
-115,430
-115,430
-237,608
-263,140
-313,948
Total Expenses
143,404
143,404
317,090
354,404
368,031
Net Income from Continuing & Discontinued Operation
-57,247
-57,247
-217,570
-254,153
-292,213
Normalized Income
-90,320
-90,320
-196,665
-253,921
-291,774
Interest Income
10,875
10,875
12,413
2,932
88
Net Interest Income
10,875
10,875
12,413
2,932
88
EBIT
-105,542
-105,542
-216,703
-262,908
-313,509
EBITDA
-98,446
-98,446
-206,418
-251,375
-297,159
Reconciled Cost of Revenue
22,563
22,563
16,918
26,219
21,908
Reconciled Depreciation
7,096
7,096
10,285
11,533
16,350
Net Income from Continuing Operation Net Minority Interest
-57,247
-57,247
-217,570
-254,153
-292,213
Total Unusual Items Excluding Goodwill
33,073
33,073
-20,905
-232
-439
Total Unusual Items
33,073
33,073
-20,905
-232
-439
Normalized EBITDA
-131,519
-131,519
-185,513
-251,143
-296,720
12/31/2021 - 11/3/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BLUE bluebird bio, Inc.
4.1400
-0.24%
TVTX Travere Therapeutics, Inc.
14.92
+2.40%
SAGE Sage Therapeutics, Inc.
7.43
+0.81%
SYRE Spyre Therapeutics, Inc.
12.67
+2.01%
GYRE Gyre Therapeutics, Inc.
8.88
+11.84%
VYGR Voyager Therapeutics, Inc.
3.1600
+0.96%
OABI OmniAb, Inc.
1.7900
+1.13%
SPRB Spruce Biosciences, Inc.
0.1187
-3.50%
CRGX CARGO Therapeutics, Inc.
4.6400
0.00%
FOLD Amicus Therapeutics, Inc.
6.83
+1.94%